SAM Chun Dang Pharm

삼천당제약 · 000250

Health Care Pharmaceuticals · KOSDAQ

Large-cap

Market cap US$5.1B (₩7.1T)

Overview

SAM Chun Dang Pharm makes prescription medicines, including antibiotics, cardiovascular treatments, digestive-disease drugs, and eye drops, supplied to hospitals and pharmacies in South Korea.

It is listed on KOSDAQ, South Korea's tech and small-cap exchange. The company operates through subsidiaries that manufacture ophthalmic preparations and support export approvals in North America and Japan, making its eye-care and international operations a distinct part of its business alongside the core domestic prescription-drug line.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$168M

▲ +9.9% YoY

Operating profit · FY2025

US$6.1M

▲ +220.5% YoY

Net income · FY2025

US$8.7M

Turned profitable

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$139.6M(₩192.7B)	US$152.8M(₩210.9B)	US$168M(₩231.8B)
Operating profit	US$6.9M(₩9.6B)	US$1.9M(₩2.6B)	US$6.1M(₩8.5B)
Net income	−US$3M(−₩4.2B)	−US$3.7M(−₩5.1B)	US$8.7M(₩12B)

Revenue

FY2023US$139.6M
FY2024US$152.8M
FY2025US$168M

Operating profit

FY2023US$6.9M
FY2024US$1.9M
FY2025US$6.1M

Net income

FY2023−US$3M
FY2024−US$3.7M
FY2025US$8.7M

Key ratios (FY2025)

ROE

3.3%

Debt/Eq

54.4%

Op. margin

3.6%

Net margin

5.2%

Rev. YoY

▲ +9.9%

Why it matters

Its subsidiary Optus Pharm specialises in eye-drop and ophthalmic drug manufacturing, while SCD US, INC and SCD BIOTECH, LLC handle product certification and approvals for North American exports.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?